GlassScriptPhysician profile
Claudio Osorio
NPI 1750676706
$11,516.60
in general payments reported to CMS, 2019-2025
34 companies · $3,073 in 2025
The $3,073 reported for 2025 was more than what 82% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $508 · 2021: $1,275 · 2022: $2,830 · 2023: $3,325 · 2024: $505 · 2025: $3,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,531 · Travel and Lodging: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,531.10 |
| Travel and Lodging | $1,371.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,974.07 | 2020-2025 | Fintepla, Nayzilam, Briviact |
| Livanova USA, INC. | $1,926.67 | 2021-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,269.54 | 2021-2025 | |
| Eisai INC. | $833.51 | 2020-2025 | |
| Sk Life Science, INC. | $671.85 | 2021-2025 | Xcopri |
| Jazz Pharmaceuticals INC. | $654.04 | 2022-2025 | Epidiolex |
| Neurelis, INC. | $533.94 | 2020-2025 | Valtoco |
| Lilly USA, LLC | $468.15 | 2020-2023 | Emgality, Reyvow, Amyvid |
| Argenx US, INC. | $451.85 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $327.74 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $295.55 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $272.68 | 2022-2025 | Austedo Xr, Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $217.97 | 2022 | |
| Amgen INC. | $214.38 | 2020-2022 | |
| Allergan, INC. | $136.19 | 2020-2022 |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudio Osorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.